Last reviewed · How we verify
Ortho Cyclen
Ortho Cyclen, marketed by ViiV Healthcare, is a well-established product in its therapeutic class, though specific details on its mechanism and primary indication are not provided. A key strength of Ortho Cyclen is its secured market presence until at least 2028, when the key composition patent expires. The primary risk to consider is the potential increase in competition post-2028, which could impact revenue.
At a glance
| Generic name | Ortho Cyclen |
|---|---|
| Also known as | Orthocyclen, Sprintec, Previfem, MonoNessa |
| Sponsor | ViiV Healthcare |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Shortened Regimen for Drug-susceptible TB in Children (PHASE3)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants (PHASE1)
- A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity (PHASE1)
- A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012) (PHASE1)
- Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants (PHASE1)
- A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD. (PHASE1)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ortho Cyclen CI brief — competitive landscape report
- Ortho Cyclen updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI